Latest filings (excl ownership)
425
Business combination disclosure
12 Apr 24
6-K
Agreement and Plan of Merger
11 Apr 24
S-8
Registration of securities for employees
1 Apr 24
20-F
2023 FY
Annual report (foreign)
1 Apr 24
6-K
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
27 Mar 24
6-K
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
15 Mar 24
6-K
Report of Foreign Private Issuer
13 Mar 24
6-K
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
8 Mar 24
EFFECT
Notice of effectiveness
7 Mar 24
6-K
Report of Foreign Private Issuer
29 Feb 24
F-1
Registration statement (foreign)
27 Feb 24
6-K
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
27 Feb 24
6-K
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
20 Feb 24
6-K
Report of Foreign Private Issuer
12 Feb 24
6-K
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
29 Jan 24
6-K
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
25 Jan 24
6-K
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
22 Jan 24
UPLOAD
Letter from SEC
18 Jan 24
CORRESP
Correspondence with SEC
5 Jan 24
UPLOAD
Letter from SEC
21 Dec 23
6-K
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
8 Dec 23
8-A12B
Registration of securities on exchange
28 Nov 23
6-K
Report of Foreign Private Issuer
28 Nov 23
6-K
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
28 Nov 23
6-K
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
27 Nov 23
EFFECT
Notice of effectiveness
24 Nov 23
6-K
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
22 Nov 23
F-3/A
Shelf registration (foreign) (amended)
20 Nov 23
CORRESP
Correspondence with SEC
20 Nov 23
F-3
Shelf registration (foreign)
3 Nov 23
6-K
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
31 Oct 23
6-K
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
24 Oct 23
D
$5.03 mm in options, sold $5.03 mm, 1 investor
19 Oct 23
6-K
Report of Foreign Private Issuer
18 Oct 23
6-K
Interim Consolidated Financial Statements
16 Oct 23
6-K
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
16 Oct 23
6-K
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
12 Oct 23
6-K
SciSparc Granted European Patent for its Core Technology
3 Oct 23
6-K
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
29 Sep 23
6-K
SciSparc Announces 1-for-26 Reverse Share Split
21 Sep 23
Latest ownership filings
SC 13G
YA II PN, Ltd.
6 Mar 24
144
Notice of proposed sale of securities
21 Aug 23
SC 13G
Clearmind Medicine Inc.
13 Dec 22
SC 13G/A
EIDE ROBERT J
9 May 22
SC 13G/A
BIGGER CAPITAL FUND L P
11 Feb 22
SC 13G/A
BIGGER CAPITAL FUND L P
1 Feb 21
SC 13G
EIDE ROBERT J
9 Dec 20
SC 13D/A
L.I.A. Pure Capital Ltd
3 Dec 20
SC 13G
BIGGER CAPITAL FUND L P
30 Nov 20
SC 13G/A
MORGAN STANLEY
10 Aug 20
SC 13D/A
L.I.A. Pure Capital Ltd
1 Jul 20
SC 13D/A
L.I.A. Pure Capital Ltd
26 Jun 20
SC 13D/A
L.I.A. Pure Capital Ltd
9 Jun 20
SC 13D
L.I.A. Pure Capital Ltd
2 Jun 20
SC 13G
MORGAN STANLEY
30 Apr 20
SC 13G/A
Therapix Biosciences Ltd.
12 Feb 19
SC 13G
Therapix Biosciences Ltd.
13 Apr 17